Anas Younes: Decade-Long Persistence of CD19 CAR T Cells in B Cell Lymphomas
oncodaily - Anas Younes, Chief Medical Officer and Head of Haematology R&D at AstraZeneca, shared on LinkedIn: “While these findings demonstrate that CART19 cells can persist for more than 10 years in […]
AI Summary: Long-term follow-up shows CD19-directed CAR‑T cells can persist for a decade in patients with B‑cell lymphomas, associating with sustained remissions and reshaping expectations about durability, retreatment and long-term toxicity. These findings prompt rethinking of follow-up care and suggest cellular therapies may offer far longer benefits than anyone dared hope.
ASTRO updates guideline on radiation therapy for pancreatic cancer
medicalxpress - An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer.
AI Summary: ASTRO released updated 2026 guidance for radiation therapy in pancreatic cancer, refining target volumes, dose constraints, and technique recommendations. The update aims to standardize practice, improve safety for nearby organs at risk, and incorporate emerging evidence on hypofractionation and concurrent systemic therapies to better balance local control with toxicity.
Calls for Forests Minister Ravi Parmar to resign intensify amid wildfire crisis
Alex Zoltan / westernstandard - PENTICTON — The Conservative Party of BC, and others, are intensifying calls for Forests Minister Ravi Parmar to resign, citing multiple mill closures that cost hundreds of high-paying jobs and the government’s handling of a destructive wildfire season th…
AI Summary: A four‑part investigative series explores pre‑surgical complications, documenting common causes, system shortcomings, and patient experiences. The reporting synthesizes clinical evidence and expert commentary to recommend perioperative safeguards, communication improvements, and policy changes designed to reduce avoidable harm and improve surgical outcomes.
- Imaging and tech reshaping surgical planning (4)
- Pre-op optimization and outcome drivers (4)
- Safety culture, decisions and system failures (3)
- All Other Stories
Imaging and tech reshaping surgical planning
Pre-op optimization and outcome drivers
Safety culture, decisions and system failures
All Other Stories
Essentia Health names EVP from SSM Health
Kelly Gooch / beckershospitalreview - Jason Craig, most recently a regional vice president at St. Louis-based SSM Health, was named executive vice president of administration and operations at Duluth, Minn.-based Essentia Health, according to an Aug. 12 news release shared with Becker’s. Mr. …
AI Summary: Recent analyses and expert commentary propose that genomic newborn screening can identify children with cancer predisposition syndromes before tumors develop. Early detection would enable targeted surveillance and preventive measures, though ethical, logistical, and equity considerations remain central to implementing such programs at scale. Expect lively debate before universal adoption.
Air pollution-linked blood changes detected years before lung cancer diagnosis
medicalxpress - A new study, published Tuesday in Nature Communications, found measurable changes in people's blood associated with exposure to air pollution and the subsequent development of lung cancer. The findings provide promising clues that could help shape future …
AI Summary: New analyses link long‑term air pollution exposure to distinct blood metabolic and biomarker changes that appear years before lung cancer diagnosis, suggesting a window for earlier detection. The work identifies candidate pathways tying inhaled pollutants to carcinogenic processes and proposes blood‑based signals for future screening or risk stratification.
CMS ends Medicaid, CHIP funding for gender-affirming care for minors
fiercehealthcare - The Trump administration has finalized a rule that would pull funding gender-affirming care for minors from Medicaid and the Children's Health Insurance Program.
AI Summary: CMS announced a policy change ending Medicaid and CHIP funding for gender‑affirming care for minors, effectively narrowing federal support and prompting immediate concern from providers, families and advocacy groups. The move is expected to produce a patchwork of state responses, legal challenges and disrupted care pathways as clinicians and health systems adjust to suddenly constrained coverage.
Lucy Davis Reveals Incurable Stage 4 Breast Cancer: Diagnosis, Bone Metastases, and What We Know
oncodaily - British actress Lucy Davis, best known for playing Dawn Tinsley in the original UK version of The Office, has revealed that she has been living with stage 4 breast cancer […]
AI Summary: Actor Lucy Davis disclosed a diagnosis of incurable stage‑4 breast cancer with bone metastases, using her platform to raise awareness about prognosis, screening and self‑examination. Her candid account underscores the reality of metastatic disease and encourages people to pay attention to subtle changes, not just lumps.
Wolfgang Miesbach: JAMA Updates Rules on AI Use in Medical Publishing
oncodaily - Wolfgang Miesbach, Head of the Department of Haemostaseology and the Haemophilia Center of Medical Clinic 2 and Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn: “JAMA […]
AI Summary: JAMA updated its authorship and disclosure policies to clarify acceptable uses of generative AI in medical publishing, tightening requirements and banning unacknowledged AI contributions. The guidance aims to preserve scientific integrity while acknowledging AI’s growing role — yes, the journal is telling computers to behave themselves.
Health IT Vendor’s Data Breach Exposes Nearly 4M Patient Records
Katie Adams / medcitynews - Revenue cycle vendor Unlimited Technology Systems disclosed a ransomware attack affecting 3.8 million patients — the second-largest healthcare data breach reported to HHS this year.The post Health IT Vendor’s Data Breach Exposes Nearly 4M Patient Records …
AI Summary: A ransomware attack on a health IT vendor exposed nearly four million patient records, prompting urgent security reviews and fresh scrutiny of vendor controls. The incident highlights systemic vulnerabilities in healthcare data protections, spurred regulatory attention and calls for tighter oversight across third‑party technology providers.
Providence to completely exit insurance business after Medicare Advantage deal falls through
Jakob Emerson / beckershospitalreview - Providence Health Plan will completely shut down after it was unable to reach a deal with a national insurer to operate its Medicare Advantage business. “We are in discussion with regulators about this development and the broader wind-down of Providence’s…
AI Summary: Providence announced it will completely exit the insurance business after a proposed Medicare Advantage transaction fell apart, triggering a wind‑down of its health plan. The move comes amid a broader operational turnaround that has shown sizable improvements but forces the system to refocus on core provider operations and financial stabilization.
- Providence $400M turnaround and CFO appointment (4)
- Providence Health Plan exits after Medicare Advantage deal (4)
- All Other Stories
Providence $400M turnaround and CFO appointment
Providence Health Plan exits after Medicare Advantage deal
All Other Stories
FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma
oncodaily - The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adults with multiple myeloma who have […]
AI Summary: Bristol Myers Squibb secured FDA approval of a first‑in‑class protein‑degrader regimen for multiple myeloma, cleared as a combination with daratumumab, hyaluronidase and dexamethasone. The nod marks a notable shift toward targeted degrader strategies in hematologic oncology and gives clinicians another option for patients with advanced disease.